Stocks · News reference
Ionis Pharmaceuticals received an analyst rating upgrade to 'Outperform' from 'Market Perform,' alongside a price target increase to $66.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Ionis Pharmaceuticals provided support for a new white paper from the National Triglyceride Alliance that highlights gaps in the care and management of patients with severe hypertriglyceridemia.
Health Canada has granted approval for Hibsago (bepirovirsen), an antisense oligonucleotide developed by GSK in collaboration with Ionis Pharmaceuticals, for the treatment of chronic hepatitis B.
Ionis Pharmaceuticals has scheduled a live webcast for November 9, 2026, to discuss its third quarter 2026 financial results and provide updates on key programs.
Roche has entered into a licensing agreement with Ionis Pharmaceuticals to acquire the rights to sefaxersen for the treatment of complement-mediated diseases.
Roche announced positive interim phase III data from the IMAgINATION study showing that investigational sefaxersen achieved a statistically significant 43.1% reduction in proteinuria relative to placebo at 37 weeks in adults with primary IgA nephropathy. The antisense oligonucleotide inhibitor of complement factor B was well tolerated with no new safety signals and is designed as a once-monthly subcutaneous injection for self-administration.
Filed: 2026-10-23 AccNo: 0001140361-26-040631 Size: 186 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits